Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Invested Capital (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Invested Capital for 13 consecutive years, with $942.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 8.1% to $942.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $942.6 million, a 8.1% increase, with the full-year FY2025 number at $942.6 million, up 8.1% from a year prior.
  • Invested Capital was $942.6 million for Q4 2025 at Madrigal Pharmaceuticals, down from $965.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $973.7 million in Q2 2024 to a low of $78.5 million in Q3 2022.
  • A 5-year average of $502.6 million and a median of $268.9 million in 2021 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: crashed 66.57% in 2022, then surged 422.52% in 2024.
  • Madrigal Pharmaceuticals' Invested Capital stood at $196.1 million in 2021, then surged by 36.18% to $267.1 million in 2022, then surged by 95.01% to $520.8 million in 2023, then skyrocketed by 67.42% to $872.0 million in 2024, then increased by 8.1% to $942.6 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Invested Capital are $942.6 million (Q4 2025), $965.5 million (Q3 2025), and $814.4 million (Q2 2025).